We thank Dr. Toussirot and Dr. Dumoulin for their comments on our paper.

We are pleased to see that they recently published similar results in a group of 12 patients with spondyloarthritis (SpA). Indeed, our study was actually performed on a Hologic Delphi-W device, not a QDR 2000. We gave the results in cm², because that is how the results were presented in the validation paper, knowing that the correlation between visceral fat area (cm²), volume (cm³), and mass (g) on this software is completely linear ($r = 1$, $p < 0.0001$); mass (g) = area (cm²) × 4.8213072, and volume (cm³) = area (cm²) × 5.212224. We agree that the relevance of the results is based on the validity of the measurement tool. The authors used the CoreScan software, which was validated by comparison to computed tomography (CT) scans. We used Visceral Adipose Tissue software, which was also validated by comparison to CT scans.

Beyond these technical considerations, the issue is that the 2 studies indicate that a change in fat mass, and in visceral fat, is observed in patients with SpA receiving longterm administration of tumor necrosis factor-α blockers. Thus, we agree that these data are the basis for further studies on potential change in cardiovascular risk in these patients.

REFERENCES

J Rheumatol 2014;41:12; doi:10.3899/jrheum.141160